New network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
List view / Grid view
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines. Its benefits mean it is poised to disrupt the $87 billion pain management market and…
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
Researchers have developed a system that enabled quantitative assessment of cytotoxicity of SiNPs in human hepatoma cells.
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
19 May 2023 | By CN Bio
A discussion of the recently published paper, “Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation-based Assay,” and how the field can produce more replicable experiments.
Learning about the mitochondrial role in a neurodegenerative disorder.
Using Agilent Seahorse XF technology with the XF Mito Tox Assay allows for streamlined, reliable identification of mitochondrial toxicants.
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
This whitepaper establishes a customised XF assay solution for the detection of mitochondrial toxicity using standardised parameters.